Health and Pharma

25/07/2025

How do you target a complex, glycosylated checkpoint like without sacrificing specificity? 🤔
In our latest ONCOLife interview, Pheast Therapeutics CMO Dr. Raphaël Rousseau, MD, PhD, explains how clinical‑stage antibody engages the innate immune system by blocking a key “ ” signal in high‑need .

Dr. Raphaël Rousseau: Macrophage checkpoint inhibitors promise a transformative role in cancer immunotherapy; by targeting the “don’t eat me” signal CD24, they could address the shortcomings of T-cell therapies, enhancing both tumor specificity and safety.

25/07/2025

The START Center for Cancer Research for Research has announced a strategic partnership with Advarra to accelerate and streamline early-phase trials across its global network. By integrating Advarra’s regulatory expertise and advanced solutions, including a CTMS and eReg platform, the collaboration aims to build a more connected, efficient, and patient-centric research ecosystem.

The START Center for Cancer Research has announced a strategic partnership with Advarra to accelerate and streamline early-phase oncology trials across its global network. By integrating Advarra’s regulatory expertise and advanced technology solutions

24/07/2025

The American Cancer Society (ACS) and its advocacy arm, the American Cancer Society Cancer Action Network (ACS CAN), have appointed Shane Jacobson as their new Chief Executive Officer. This leadership transition marks a pivotal moment for ACS as it continues to expand its efforts in cancer research, policy advocacy, and patient support. Jacobson, a respected leader in nonprofit healthcare, currently serves as CEO of the V Foundation for Cancer Research.

The American Cancer Society (ACS) and its advocacy arm, the American Cancer Society Cancer Action Network (ACS CAN), have appointed Shane Jacobson as their new Chief Executive Officer, effective August 12, 2025.

24/07/2025

The the V Foundation for Cancer Research has appointed Clark Kinlin as Interim CEO, following the departure of Shane Jacobson, who will assume the role of CEO at the American Cancer Society. Kinlin, a longtime board member and former president of Corning Optical Communications, brings deep institutional knowledge and strategic insight to guide the organization through its next phase.

The V Foundation for Cancer Research has appointed Clark Kinlin as Interim CEO, following the departure of Shane Jacobson, who will assume the role of CEO at the American Cancer Society.

17/07/2025

In this exclusive, John Santini, CEO of Vergent , reveals how intraoperative molecular with is reshaping the future of surgery. We dive into the groundbreaking VISUALIZE Phase 2B study, which showed that abenacianine identified tumors missed by standard methods in 45% of cases—enabling more complete, accurate, and tissue-sparing resections.
https://healthandpharma.net/abenacianine-john-santini-lung-cancer-surgery

16/07/2025

� Join us for an exclusive interview with Dr. John Gribben, Professor at the Cancer Institute in London and Past President of EHA. Dr. Gribben shares his expert perspective on the clinical and systemic challenges limiting access to CAR T-cell therapy.
We’ll explore:
� The current landscape and treatment potential of CAR T-cell therapy
� Why access remains limited for many eligible patients
� The policy and infrastructure changes needed to expand access
� The goal to double CAR T access by 2030 — and how we get there



� New to streaming or looking to level up? Check out StreamYard and get $10 discount! �

02/07/2025

� Exclusive Interview � LIVE Today at 3 PM ET
Join us for a powerful conversation with Dr. Miguel-Angel Perales, Co-Chair of the CAR T Vision initiative and a global expert in stem cell transplantation and cellular therapy. Dr. Perales will shares his expert insights on the major barriers preventing eligible patients from accessing CAR T therapy, including delayed referrals, limited treatment capacity, and systemic funding challenges.

We’ll explore:
� Why so many eligible patients still can’t access CAR T-cell therapy
� The bold mission to double access by 2030
� How we can break down systemic barriers and expand treatment capacity
� What the future holds for CAR T and other cellular therapies

-T

� New to streaming or looking to level up? Check out StreamYard and get $10 discount! �

27/06/2025

Empowering Patients to Expand Access to CAR T-cell Therapy
We’re honored to share our exclusive interview with Lorna Warick, CEO of Lymphoma Coalition, where she provides a powerful perspective on one of the most promising — yet underutilized — treatments in care: .
� In this conversation, we discuss:
� The real-world barriers patients face in accessing
� The importance of culturally sensitive, evidence-based information
� How global advocacy can drive change in care pathways and policy
� The goal to double patient access to CAR T- by 2030

-TVision

� New to streaming or looking to level up? Check out StreamYard and get $10 discount! �

19/06/2025

🚀 START Hope Hub is live! A game-changer in cancer research access. With 720+ active trials, this digital platform connects patients, physicians, and advocacy groups to early-phase studies. It’s smarter, faster, and more human.

The START Center for Cancer Research announced the launch of the START Hope Hub, a digital platform providing access to over 720 active oncology clinical trials.

09/06/2025

Presented at , new post-hoc analyses from the Phase III showed that ( ) plus ADT extended the time to HRQoL deterioration by 5.1 months and delayed pain progression in patients with metastatic castration-sensitive ( ), with improvements observed in social/family and functional well-being.

Presented at ASCO 2025, new post-hoc analyses from the Phase III ARANOTE trial showed that darolutamide (Nubeqa) plus ADT extended the time to HRQoL deterioration by 5.1 months and delayed pain progression in patients with mCSPC

08/06/2025

The new results from the ATOMIC trial, show that ( ) plus FOLFOX chemotherapy halved the risk of recurrence or death in stage III dMMR , boosting three-year disease-free survival to 86.4% compared with 76.6% for alone. Presented at , these results position chemo- as a potential new standard of care for this subgroup.

The results from ATOMIC trial, presented at ASCO 2025, show that adding atezolizumab (Tecentriq) to FOLFOX chemotherapy halved the risk of recurrence or death in stage III dMMR colon cancer, boosting 3-year DFS to 86.4% compared with 76.6% for chemotherapy alone.

08/06/2025

Zai Lab presented new data for , an investigational DLL3-targeted antibody-drug conjugate ( ) for heavily pretreated patients with extensive-stage small cell (ES- ), at . In second-line treatment, it achieved a 67% objective response rate (ORR), including 79% at 1.6 mg/kg, with manageable toxicity below 2.0 mg/kg. Intracranial activity was observed in 68% of patients with brain metastases.
https://healthandpharma.net/adc-zl1310-lung-cancer-sclc-asco25